GLP-1 Analogs for Neuroprotection After Cardiac Arrest

NCT02442791 · Completed

Last updated 2026-05-28

This clinical trial is testing whether giving GLP-1 analogs to people who have had a cardiac arrest and are in a coma is safe and feasible.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 120 people

Who can join Ages 18+ · all sexes

Timeline Started 2014-06 · est. completion 2016-06

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02442791 ↗

Description as written by the study sponsor.

Experimental studies and previous clinical trials suggest neuroprotective effects of GLP-1 analogs in various degenerative neurological diseases, and in hypoxic brain injuries in experimental designs. This study is designed as a safety and feasibility study with patients randomized 1:1 to receive GLP-1 analogs immediately after hospital admission after out of hospital cardiac arrest.

Treatments tested

Byetta (Lilly, Exenatide) also known as Byetta Drug

See description of Arms
20% Human Albumin Other

See description of Arms

Main thing measured	Feasibility: Over 90% initiation of study drug infusion
Sponsor	Jesper Kjaergaard
Conditions studied	Cardiac Arrest, Coma
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02442791 ↗